Effect of ozanimod on circulating leukocyte subtypes in patients with relapsing multiple sclerosis and comparison with healthy volunteers

被引：0
|
作者：
Harris, S. [1 ]
Maddux, R. [1 ]
Hoffmueller, U. [2 ]
Raschke, E. [2 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
[2] Precis Med GmbH, Berlin, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P659
引用
收藏
页码：567 / 567
页数：1
相关论文
共 50 条
  • [41] Malignancy Rates With Long-term Use of Ozanimod in Relapsing Multiple Sclerosis Trials
    Hartung, H-P.
    Cree, B. A. C.
    Selmaj, K. W.
    Havrdova, E. K.
    Comi, G.
    Sheffield, J. K.
    Minton, N.
    Lindholm, A.
    Ding, N.
    Bar-or, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 330 - 331
  • [42] Incidence of confirmed macular oedema in the phase 3 program of ozanimod in relapsing multiple sclerosis
    Gross, S. A.
    Skolnick, B. E.
    Minton, N.
    Sheffield, J. K.
    Calkwood, J.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 675 - 675
  • [43] Lymphocyte Subtypes in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated with Dimethylfumarate (DMF)
    Ganguly, Rik
    Camac, Ann
    Dionne, Caitlin
    Chaves, Claudia
    NEUROLOGY, 2016, 86
  • [44] Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis
    Dubinsky, Marla C.
    Charles, Lorna
    Selmaj, Krzysztof W.
    Comi, Giancarlo
    Krakovich, Anthony
    van der Woude, C. Janneke
    Mahadevan, Uma
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S887 - S887
  • [45] Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis
    Dubinsky, Marla C.
    Charles, Lorna
    Selmaj, Krzysztof W.
    Comi, Giancarlo
    Krakovich, Anthony
    Rosen, Melissa
    van der Woude, C. Janneke
    Mahadevan, Uma
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (12) : 2512 - 2515
  • [46] Comparative efficacy and safety of ozanimod versus teriflunomide for relapsing-remitting multiple sclerosis: a matching-adjusted indirect comparison
    Cohan, S.
    Kumar, J.
    Arndorfer, S.
    Zhu, X.
    Zivkovic, M.
    Tencer, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 140 - 140
  • [47] A Matching-Adjusted Indirect C\omparison of Ozanimod to Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis
    McGinley, M.
    Paul, D.
    Branchcomb, T.
    Arndorfer, S.
    Navickas, C.
    Gupte-Singh, K.
    Kantor, D.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 39 - 39
  • [48] Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
    Millie, Long
    Raymond, Cross
    Jonathan, Calkwood
    Marc, Pondel
    Ashwini, Pai
    Harris, Ahmad
    Lorna, Charles
    Ayanbola, Elegbe
    AnnKatrin, Petersen
    James, Sheffield
    Adil, Javed
    Douglas, Wolf
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S9 - S10
  • [49] Safety and Efficacy of Ozanimod Over 1 Year in Patients with Early Relapsing Multiple Sclerosis: an Interim Analysis of the ENLIGHTEN Study
    Naismith, Robert
    Zivadinov, Robert
    Morrow, Sarah
    Bass, Ann
    Obeidat, Ahmed Zayed
    Riser, Emily
    Wray, Sibyl
    Cristofanilli, Massimiliano
    Riolo, Jon
    Thorpe, Andrew
    Chaudhry, Burhan
    Mohiuddin, Kamran
    Cheng, Chun-Yen
    Silva, Diego
    DeLuca, John
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 596 - 597
  • [50] Safety patterns with ozanimod during phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
    Selmaj, K. W.
    Ziemssen, T.
    Comi, G.
    Hartung, H. -P.
    Singal, M.
    Riolo, J. V.
    Cheng, C. -Y.
    Sheffield, J. K.
    Minton, N.
    Vermersch, P.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 641 - 642
12345